Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy)

American Heart Journal

Volumn 146, Issue 1, 2003, Pages 91-98

  Serebruany, Victor L ^a,c   Malinin, Alex I ^a   O'Connor, Christopher M ^b   Gurbel, Paul A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c SINAI HOSPITAL OF BALTIMORE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CD31 ANTIGEN; COLLAGEN; ROXIFIBAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSS LINKING; DOUBLE BLIND PROCEDURE; DRUG INHIBITION; ENDOTHELIUM CELL; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; MALE; MORTALITY; MULTICENTER STUDY; PATIENT CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; THROMBOSIS;

EID: 0038160845     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(03)00186-8     Document Type: Article

References (30)

1. Theroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation 1998;97:1195-206.
2. Simoons ML, Boersma E, van der Zwaan C, et al. The challenge of acute coronary syndromes. Lancet 1999;353(Suppl 2):SII1-4.
3. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998;98:2829-35.
4. CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349:1429-35.
5. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997;336:1689-96.
6. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998;339:436-43.
7. Trip MD, Cats VM, van Capelle FJ, et al. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990;322:1549-54.
8. Ault KA, Cannon CP, Mitchell J, et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial: Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1999;33:634-9.
9. CAPRIE Steering Committee. A randomised, blinded trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). Lancet 1996;348:1329-39.
10. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
11. Mousa SA, Kapil R, Mu DX. Intravenous and oral antithrombotic efficacy of the novel platelet GP IIb/IIIa antagonist roxifiban (DMP754) and its free acid form, XV459. Arterioscler Thromb Vasc Biol 1999;19:2535-41.
12. Ruggeri ZM. New insights into the mechanisms of platelet adhesion and aggregation. Semin Hematol 1994;31:229-39.
13. Abbate R, Favilla S, Boddi M, et al. Factors affecting platelet aggregation in whole blood. Am J Clin Pathol 1986;86:91-6.
14. Auh KA. Flow cytometric measurement of platelet function and reticulated platelets. Ann N Y Acad Sci 1993;677:293-308.
15. Serebruany VL, Ordonez JV, Herzog WR, et al. Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitro-nectin (CD51/CD61) receptor expression. J Cardiovasc Pharmacol 1997;29:16-22.
16. Gurbel PA, Serebruany VL, Shustov AR, et al. The GUSTO-III Investigators. Global use of strategies to open occluded coronary arteries: effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. J Am Coll Cardiol 1998;31:1466-73.
17. Gurbel PA, Kereiakes DJ, Dalesandro MR, et al. Role of soluble and platelet-bound P-selectin in discriminating cardiac from non-cardiac chest pain at presentation in the emergency department. Am Heart J 2000;139:320-8.
18. Coller BS, Peerschke EI, Seligsohn U, et al. Studies on the binding of an alloimmune and two murine monoclonal antibodies to the platelet glycoprotein IIb-IIIa complex receptor. J Lab Clin Med 1986;107:384-92.
19. Levy-Toledano S. Platelet signal transduction pathways: could we organize them into a "hierarchy"? Haemostasis 1999;29:4-15.
20. Harrington RA. Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes. Am Heart J 1999;138(4 Pt 2):276-86.
21. Ferguson JJ, Taqi K. IIb/IIIa receptor blockade in acute myocardial infarction. Am Heart J 1999;138(2 Pt 2):164-70.
22. Kleiman NS, Raizner AE, Jordan R, et al. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol 1995;26:1665-71.
23. Merten M, Pakala R, Thiagarajan P, et al. Platelet microparticles promote platelet interaction with subendothelial matrix in a glycoprotein IIb/IIIa-dependent mechanism. Circulation 1999;99:2577-82.
24. Holmes MB, Sobel BE, Schneider DJ. Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects. Am J Cardiol 1999;84:203-7.
25. Storey RF, Wilcox RG, Heptinstall S. Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency: implications for assay methodology and comparison of different antagonists. Circulation 1998;98:1616-21.
26. Serebruany VL, Gurbel PA. The relations of major platelet receptor expression during myocardial infarction: monitoring efficacy of GPIIb/IIIa inhibitors by measuring P-selectin? Thromb Haemost 1999;81:314-6.
27. Peter K, Schwarz M, Ylanne J, et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (αIIbβ3) inhibitors. Blood 1998;92:3240-9.
28. Holmes MB, Sobel BE, Cannon CP, et al. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Am J Cardiol 2000;85:491-3.
29. Xiao Z, Theroux P, Frojmovic MM. Modulation of platelet-neutrophil interaction with pharmacological inhibition of fibrinogen binding to platelet GP IIb/IIIa receptor. Thromb Haemost 1999;81:281-5.
30. Chew DP, Bhatt DL, Sapp S, et al. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 2001;103:201-6.